Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Eur J Cancer
; 121: 177-183, 2019 11.
Article
in En
| MEDLINE
| ID: mdl-31586757
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bone Neoplasms
/
Osteosarcoma
/
Immunoconjugates
/
Antibodies, Monoclonal
/
Neoplasm Recurrence, Local
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Language:
En
Journal:
Eur J Cancer
Year:
2019
Document type:
Article
Country of publication: